US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

27.09

+1.546.03%

Post-market: 27.090.00000.00%16:10 EST

Volume:301.71K

Turnover:8.15M

Market Cap:1.29B

PE:-9.97

High:27.60

Open:26.44

Low:26.16

Close:25.55

52wk High:42.27

52wk Low:6.43

Shares:47.66M

Float Shares:26.57M

Volume Ratio:1.18

T/O Rate:1.14%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.7168

EPS(LYR):-3.7760

ROE:-23.41%

ROA:-15.89%

PB:2.52

PE(LYR):-7.17

Loading ...

Overview Company News Filings

Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next

Rapport Therapeutics Initiated at Overweight by Wells Fargo

Wells Fargo Initiates Coverage on Rapport Therapeutics With Overweight Rating, $43 Price Target

MT Newswires Live

Rapport Therapeutics CEO Abraham Ceesay Reports Disposal of Common Shares

Analysts Conflicted on These Healthcare Names: Rapport Therapeutics, Inc. (RAPP) and Moderna (MRNA)

Rapport Therapeutics Chief Scientific Officer David Bredt Reports Sale of Common Shares

A Look At Rapport Therapeutics (RAPP) Valuation After FDA Clears Phase 3 Trial For RAP-219

Simply Wall St.

FDA Phase 3 Green Light for RAP-219 Might Change The Case For Investing In Rapport Therapeutics (RAPP)

Simply Wall St.

Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating

Have Rapport Therapeutics Insiders Been Selling Stock?

Simply Wall St.

Rapport Therapeutics Inc - FDA Allows Rap-219 Advancement Into Registrational Trials for Fos

THOMSON REUTERS

Rapport Therapeutics Inc: Accelerated Initiation of Rap-219 Phase 3 Program Expected in Q2 of 2026

THOMSON REUTERS

Rapport Therapeutics Inc: Plans to Initiate a Phase 3 Trial of Rap-219 in Pgtcs in First Half of 2027

THOMSON REUTERS

Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

Rapport Therapeutics (RAPP): Valuation Check After Joining the S&P Pharmaceuticals Select Industry Index

Simply Wall St.

How RAP-219 Phase 2a Data and 2026 Phase 3 Plans At Rapport Therapeutics (RAPP) Has Changed Its Investment Story

Simply Wall St.

Rapport Therapeutics CEO Abraham Ceesay Reports Disposal of Common Shares

Rapport Therapeutics Chief Scientific Officer David Bredt Reports Sale of Common Shares

Assessing Rapport Therapeutics (RAPP) Valuation After Positive RAP-219 Phase 2a Epilepsy Data and Phase 3 Plans

Simply Wall St.

Rapport Therapeutics Is Maintained at Buy by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RAPP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":27.09,"timestamp":1770411600000,"preClose":25.55,"halted":0,"volume":301708,"hourTrading":{"tag":"盘后","latestPrice":27.09,"preClose":27.09,"latestTime":"16:10 EST","volume":2175,"amount":58920.75,"timestamp":1770412204943,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.060273972602739694,"floatShares":26567199,"shares":47661138,"eps":-2.716762,"marketStatus":"Market Closed","change":1.54,"latestTime":"02-06 16:00:00 EST","open":26.44,"high":27.6,"low":26.16,"amount":8154645.0778,"amplitude":0.05636,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.716762,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":25.55,"postHourTrading":{"tag":"盘后","latestPrice":27.09,"preClose":27.09,"latestTime":"16:10 EST","volume":2175,"amount":58920.75,"timestamp":1770412204943,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1846394385662888,"impliedVol":0.5912,"impliedVolPercentile":0.1235},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":26567199,"roa":"-15.89%","roe":"-23.41%","lyrEps":-3.775953,"volumeRatio":1.1846394385662888,"shares":47661138,"dividePrice":0,"high":27.6,"amplitude":0.05636,"preClose":25.55,"low":26.16,"week52Low":6.43,"pbRate":"2.52","week52High":42.2685,"institutionHeld":0,"latestPrice":27.09,"eps":-2.716762,"divideRate":0,"volume":301708,"delay":0,"ttmEps":-2.716762,"open":26.44,"prevYearClose":30.34,"prevWeekClose":26.61,"prevMonthClose":26.61,"prevQuarterClose":30.34,"fiveDayClose":26.61,"twentyDayClose":28.31,"sixtyDayClose":24.915},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"RAPP","fiscalQuarterEnding":"2025/09","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.71},{"market":"US","date":"2025-08-07","symbol":"RAPP","fiscalQuarterEnding":"2025/06","expectedEps":-0.87,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2025-05-08","symbol":"RAPP","fiscalQuarterEnding":"2025/03","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-11","symbol":"RAPP","fiscalQuarterEnding":"2024/12","expectedEps":-0.62,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-0.57},{"market":"US","date":"2024-11-07","symbol":"RAPP","fiscalQuarterEnding":"2024/09","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1763528400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2026-02-06","current":-9.971429,"percent":0.381862,"low":-19.654107,"twenty":-14.128014,"median":-11.370643,"eighty":-5.617345,"high":-3.640031,"avg":-10.348757,"sd":4.103842,"marketCap":1217742075},"quantilePoints":[{"date":"2024-06-07","current":-14.341434,"twenty":-13.293406,"median":-11.721364,"eighty":-11.721364,"marketCap":735830305},{"date":"2024-06-14","current":-17.322989,"twenty":-16.966549,"median":-15.024031,"eighty":-12.769392,"marketCap":888807905},{"date":"2024-06-21","current":-15.733266,"twenty":-17.881887,"median":-15.772475,"eighty":-14.348329,"marketCap":807242405},{"date":"2024-06-28","current":-16.581593,"twenty":-17.17471,"median":-16.18238,"eighty":-14.635158,"marketCap":850768389},{"date":"2024-07-05","current":-17.059223,"twenty":-17.829134,"median":-16.431888,"eighty":-15.672154,"marketCap":875274616},{"date":"2024-07-12","current":-18.299635,"twenty":-18.057796,"median":-16.595851,"eighty":-15.733266,"marketCap":938917651},{"date":"2024-07-19","current":-14.343149,"twenty":-18.092899,"median":-16.610109,"eighty":-15.733266,"marketCap":735918314},{"date":"2024-07-26","current":-16.431888,"twenty":-18.057796,"median":-16.50674,"eighty":-14.592658,"marketCap":843087333},{"date":"2024-08-02","current":-15.740395,"twenty":-18.021611,"median":-16.417631,"eighty":-14.614044,"marketCap":807608170},{"date":"2024-08-09","current":-11.062669,"twenty":-17.829134,"median":-16.189509,"eighty":-14.507112,"marketCap":697147270},{"date":"2024-08-16","current":-12.078391,"twenty":-17.822005,"median":-15.897228,"eighty":-14.341434,"marketCap":761156070},{"date":"2024-08-23","current":-12.943207,"twenty":-17.322989,"median":-15.776039,"eighty":-12.769083,"marketCap":815654991},{"date":"2024-08-30","current":-12.623979,"twenty":-17.301602,"median":-15.672154,"eighty":-12.252515,"marketCap":795537939},{"date":"2024-09-06","current":-11.799793,"twenty":-17.107699,"median":-14.956226,"eighty":-12.030797,"marketCap":743599370},{"date":"2024-09-13","current":-11.027844,"twenty":-17.007896,"median":-14.603351,"eighty":-11.813723,"marketCap":694952683},{"date":"2024-09-20","current":-12.322165,"twenty":-16.6871,"median":-14.421566,"eighty":-11.752199,"marketCap":776518182},{"date":"2024-09-27","current":-12.380206,"twenty":-16.587296,"median":-14.342291,"eighty":-11.752199,"marketCap":780175827},{"date":"2024-10-04","current":-12.072587,"twenty":-16.581593,"median":-13.041877,"eighty":-11.742318,"marketCap":760790305},{"date":"2024-10-11","current":-12.798103,"twenty":-16.461829,"median":-12.783593,"eighty":-11.721364,"marketCap":806510876},{"date":"2024-10-18","current":-15.061713,"twenty":-16.461829,"median":-13.041877,"eighty":-11.742318,"marketCap":949159059},{"date":"2024-10-25","current":-14.057599,"twenty":-16.431888,"median":-14.106934,"eighty":-11.752199,"marketCap":885881788},{"date":"2024-11-01","current":-14.289764,"twenty":-16.420482,"median":-14.289764,"eighty":-11.78122,"marketCap":900512371},{"date":"2024-11-08","current":-13.587752,"twenty":-16.360601,"median":-14.196898,"eighty":-11.792828,"marketCap":976225637},{"date":"2024-11-15","current":-10.665545,"twenty":-16.293733,"median":-13.709352,"eighty":-11.752199,"marketCap":766276774},{"date":"2024-11-22","current":-11.755009,"twenty":-16.213426,"median":-13.641207,"eighty":-11.719637,"marketCap":844550392},{"date":"2024-11-29","current":-11.627735,"twenty":-16.188083,"median":-13.405914,"eighty":-11.573511,"marketCap":835406277},{"date":"2024-12-06","current":-10.416089,"twenty":-16.139607,"median":-12.943207,"eighty":-11.450385,"marketCap":748354310},{"date":"2024-12-13","current":-9.555718,"twenty":-15.982774,"median":-12.73716,"eighty":-11.371152,"marketCap":686540097},{"date":"2024-12-20","current":-9.199351,"twenty":-15.858733,"median":-12.415031,"eighty":-11.254059,"marketCap":660936577},{"date":"2024-12-27","current":-9.688083,"twenty":-15.824515,"median":-12.350651,"eighty":-11.045256,"marketCap":696049976},{"date":"2025-01-03","current":-9.917175,"twenty":-15.797425,"median":-12.316361,"eighty":-10.975704,"marketCap":712509382},{"date":"2025-01-10","current":-7.539701,"twenty":-15.740395,"median":-12.304752,"eighty":-10.859002,"marketCap":541697328},{"date":"2025-01-17","current":-6.460419,"twenty":-15.733266,"median":-12.215086,"eighty":-10.644772,"marketCap":464155239},{"date":"2025-01-24","current":-7.076424,"twenty":-15.684376,"median":-12.087097,"eighty":-10.43238,"marketCap":508412752},{"date":"2025-01-31","current":-8.354253,"twenty":-15.597056,"median":-11.915876,"eighty":-10.137105,"marketCap":600219659},{"date":"2025-02-07","current":-8.211706,"twenty":-15.257893,"median":-11.843324,"eighty":-9.686047,"marketCap":589978251},{"date":"2025-02-14","current":-8.094614,"twenty":-15.103195,"median":-11.828814,"eighty":-9.441681,"marketCap":581565666},{"date":"2025-02-21","current":-6.455328,"twenty":-15.070846,"median":-11.799793,"eighty":-9.297098,"marketCap":463789474},{"date":"2025-02-28","current":-5.106225,"twenty":-15.037336,"median":-11.771597,"eighty":-9.077168,"marketCap":366861863},{"date":"2025-03-07","current":-4.373128,"twenty":-15.01412,"median":-11.747556,"eighty":-8.771711,"marketCap":314191765},{"date":"2025-03-14","current":-4.898381,"twenty":-14.977526,"median":-11.717047,"eighty":-8.416363,"marketCap":383577552},{"date":"2025-03-21","current":-4.530187,"twenty":-14.817535,"median":-11.627735,"eighty":-8.164869,"marketCap":354745367},{"date":"2025-03-28","current":-4.68399,"twenty":-14.676319,"median":-11.461087,"eighty":-7.790176,"marketCap":366789191},{"date":"2025-04-04","current":-4.189957,"twenty":-14.640334,"median":-11.410917,"eighty":-7.133443,"marketCap":328102968},{"date":"2025-04-11","current":-4.315796,"twenty":-14.632186,"median":-11.370643,"eighty":-6.989878,"marketCap":337957006},{"date":"2025-04-17","current":-4.730597,"twenty":-14.622599,"median":-11.327444,"eighty":-6.74653,"marketCap":370438835},{"date":"2025-04-25","current":-4.949801,"twenty":-14.60549,"median":-11.189913,"eighty":-6.457364,"marketCap":387604034},{"date":"2025-05-02","current":-5.280719,"twenty":-14.55844,"median":-11.048158,"eighty":-5.528775,"marketCap":413517298},{"date":"2025-05-09","current":-4.693792,"twenty":-14.472894,"median":-10.976093,"eighty":-5.332796,"marketCap":374099938},{"date":"2025-05-16","current":-4.560992,"twenty":-14.4176,"median":-10.940782,"eighty":-5.2164,"marketCap":363515647},{"date":"2025-05-23","current":-5.092192,"twenty":-14.397354,"median":-10.8247,"eighty":-5.097805,"marketCap":405852811},{"date":"2025-05-30","current":-3.896992,"twenty":-14.370288,"median":-10.665545,"eighty":-4.981023,"marketCap":310594193},{"date":"2025-06-06","current":-5.646289,"twenty":-14.346875,"median":-10.527934,"eighty":-4.950803,"marketCap":450014853},{"date":"2025-06-13","current":-5.101351,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"marketCap":406582762},{"date":"2025-06-20","current":-5.050978,"twenty":-14.341434,"median":-10.309179,"eighty":-5.014344,"marketCap":402568031},{"date":"2025-06-27","current":-5.408165,"twenty":-14.289764,"median":-9.866266,"eighty":-5.000606,"marketCap":431036124},{"date":"2025-07-03","current":-5.513507,"twenty":-14.247974,"median":-9.698265,"eighty":-5.011596,"marketCap":439432031},{"date":"2025-07-11","current":-7.043002,"twenty":-14.172521,"median":-9.586263,"eighty":-5.043651,"marketCap":561334272},{"date":"2025-07-18","current":-6.795718,"twenty":-14.077333,"median":-9.430989,"eighty":-5.078884,"marketCap":541625526},{"date":"2025-07-25","current":-7.610838,"twenty":-13.779001,"median":-9.362262,"eighty":-5.090926,"marketCap":606591391},{"date":"2025-08-01","current":-6.57591,"twenty":-13.6976,"median":-9.168805,"eighty":-5.092192,"marketCap":524106641},{"date":"2025-08-08","current":-6.368661,"twenty":-13.694662,"median":-9.054259,"eighty":-5.099519,"marketCap":562429202},{"date":"2025-08-15","current":-6.17446,"twenty":-13.609134,"median":-8.982986,"eighty":-5.10525,"marketCap":545278924},{"date":"2025-08-22","current":-6.170327,"twenty":-13.473486,"median":-8.4968,"eighty":-5.115317,"marketCap":544913945},{"date":"2025-08-29","current":-6.943168,"twenty":-13.38251,"median":-8.407708,"eighty":-5.122916,"marketCap":613165056},{"date":"2025-09-05","current":-6.343907,"twenty":-13.171889,"median":-8.282979,"eighty":-5.126995,"marketCap":560243072},{"date":"2025-09-12","current":-9.588184,"twenty":-13.020376,"median":-8.364435,"eighty":-5.143059,"marketCap":846751744},{"date":"2025-09-19","current":-14.281097,"twenty":-13.398113,"median":-8.486618,"eighty":-5.165131,"marketCap":1261192245},{"date":"2025-09-26","current":-13.038354,"twenty":-13.650327,"median":-8.934622,"eighty":-5.176938,"marketCap":1151443158},{"date":"2025-10-03","current":-14.902468,"twenty":-13.718742,"median":-9.051713,"eighty":-5.195691,"marketCap":1316066789},{"date":"2025-10-10","current":-13.962579,"twenty":-13.896787,"median":-9.158623,"eighty":-5.223161,"marketCap":1233063277},{"date":"2025-10-17","current":-12.986138,"twenty":-13.856058,"median":-9.228454,"eighty":-5.262092,"marketCap":1146831851},{"date":"2025-10-24","current":-13.675391,"twenty":-13.856058,"median":-9.397898,"eighty":-5.294604,"marketCap":1207701093},{"date":"2025-10-31","current":-14.035682,"twenty":-13.934383,"median":-9.502263,"eighty":-5.303959,"marketCap":1239519106},{"date":"2025-11-07","current":-11.969573,"twenty":-13.970933,"median":-9.588184,"eighty":-5.319746,"marketCap":1169427252},{"date":"2025-11-14","current":-12.034803,"twenty":-13.934383,"median":-9.698265,"eighty":-5.33408,"marketCap":1175800274},{"date":"2025-11-21","current":-13.098276,"twenty":-13.915585,"median":-9.917175,"eighty":-5.342242,"marketCap":1279701555},{"date":"2025-11-28","current":-14.493474,"twenty":-13.931568,"median":-10.309179,"eighty":-5.356195,"marketCap":1416012409},{"date":"2025-12-05","current":-14.000764,"twenty":-13.954437,"median":-10.426271,"eighty":-5.376155,"marketCap":1367874660},{"date":"2025-12-12","current":-14.039791,"twenty":-13.99491,"median":-10.604143,"eighty":-5.393122,"marketCap":1371687551},{"date":"2025-12-19","current":-14.459326,"twenty":-14.050476,"median":-10.719003,"eighty":-5.431972,"marketCap":1412676130},{"date":"2025-12-26","current":-15.088628,"twenty":-14.119227,"median":-10.841851,"eighty":-5.476848,"marketCap":1474158998},{"date":"2026-01-02","current":-14.800808,"twenty":-14.281097,"median":-10.940782,"eighty":-5.513507,"marketCap":1446038926},{"date":"2026-01-09","current":-13.81051,"twenty":-14.281097,"median":-10.976093,"eighty":-5.513507,"marketCap":1349286816},{"date":"2026-01-16","current":-13.103154,"twenty":-14.237527,"median":-11.048158,"eighty":-5.513507,"marketCap":1280178166},{"date":"2026-01-23","current":-13.620256,"twenty":-14.172521,"median":-11.156822,"eighty":-5.535473,"marketCap":1330698972},{"date":"2026-01-30","current":-13.049493,"twenty":-14.13499,"median":-11.312246,"eighty":-5.592253,"marketCap":1274935441},{"date":"2026-02-06","current":-12.464095,"twenty":-14.128014,"median":-11.370643,"eighty":-5.617345,"marketCap":1217742075}],"updateTime":1770535850320},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609098307","title":"Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2609098307","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609098307?lang=en_us&edition=fundamental","pubTime":"2026-02-06 00:31","pubTimestamp":1770309060,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ($RAPP) announced an update on their ongoing clinical study. Rapport Therapeutics (NASDAQ: RAPP) has reported a key upda...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-completes-key-phase-2a-epilepsy-study-for-rap-219-what-investors-should-watch-next?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-completes-key-phase-2a-epilepsy-study-for-rap-219-what-investors-should-watch-next?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","RAPP"],"gpt_icon":0},{"id":"2608860448","title":"Rapport Therapeutics Initiated at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2608860448","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608860448?lang=en_us&edition=fundamental","pubTime":"2026-02-02 22:57","pubTimestamp":1770044220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 02, 2026 09:57 ET (14:57 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"gpt_icon":0},{"id":"2608869568","title":"Wells Fargo Initiates Coverage on Rapport Therapeutics With Overweight Rating, $43 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2608869568","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608869568?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:36","pubTimestamp":1770035805,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) has an average rating of Buy and mean price target of $51.22, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAPP"],"gpt_icon":0},{"id":"2605353446","title":"Rapport Therapeutics CEO Abraham Ceesay Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605353446","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605353446?lang=en_us&edition=fundamental","pubTime":"2026-01-23 08:00","pubTimestamp":1769126443,"startTime":"0","endTime":"0","summary":"Abraham Ceesay, Chief Executive Officer of Rapport Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nNDLcDKcn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rapport Therapeutics CEO Abraham Ceesay Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2604378801","title":"Analysts Conflicted on These Healthcare Names: Rapport Therapeutics, Inc. (RAPP) and Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604378801","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604378801?lang=en_us&edition=fundamental","pubTime":"2026-01-20 00:50","pubTimestamp":1768841418,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rapport Therapeutics, Inc. (RAPP – Research Report) and Moderna (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-rapport-therapeutics-inc-rapp-and-moderna-mrna-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-rapport-therapeutics-inc-rapp-and-moderna-mrna-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNA","BK4139","BK4548","LU0128526141.USD","BK4581","BK4501","BK4137","XBI","BK4585","RAPP","BK4534","BK4533","LABU","BK4588","LU0029874061.USD","BK4568","XLV","HCSG","BK4551","BK4007","BK4532"],"gpt_icon":0},{"id":"2604640919","title":"Rapport Therapeutics Chief Scientific Officer David Bredt Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2604640919","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604640919?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:06","pubTimestamp":1768597602,"startTime":"0","endTime":"0","summary":"David Bredt, Chief Scientific Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL784ZHp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Rapport Therapeutics Chief Scientific Officer David Bredt Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2603355196","title":"A Look At Rapport Therapeutics (RAPP) Valuation After FDA Clears Phase 3 Trial For RAP-219","url":"https://stock-news.laohu8.com/highlight/detail?id=2603355196","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603355196?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:15","pubTimestamp":1768302919,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) is back in focus after receiving FDA clearance to start Phase 3 trials of its lead candidate RAP-219 in focal onset seizures, alongside updates across its broader central nervous system pipeline.\nSee our latest analysis for Rapport Therapeutics.\nDespite the positive FDA update and broader pipeline progress, Rapport Therapeutics’ recent share price performance has been softer, with a 1 month share price return of 10.8% and a 7 day share price return of 2.39%. Its 1...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/a-look-at-rapport-therapeutics-rapp-valuation-after-fda-clea","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/a-look-at-rapport-therapeutics-rapp-valuation-after-fda-clea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2602539582","title":"FDA Phase 3 Green Light for RAP-219 Might Change The Case For Investing In Rapport Therapeutics (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602539582","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602539582?lang=en_us&edition=fundamental","pubTime":"2026-01-11 03:12","pubTimestamp":1768072342,"startTime":"0","endTime":"0","summary":"In early January 2026, Rapport Therapeutics announced that the FDA had cleared RAP-219 to enter Phase 3 registrational trials for focal onset seizures and confirmed broader pipeline progress, including bipolar mania, long-acting injectables, and a lifted clinical hold on its diabetic peripheral neuropathic pain trial.\nThis combination of an advanced late-stage epilepsy program and a broadened neurology and pain portfolio highlights Rapport’s effort to build a multi-indication franchise...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/fda-phase-3-green-light-for-rap-219-might-change-the-case-fo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/fda-phase-3-green-light-for-rap-219-might-change-the-case-fo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AI","BK4551","BK4543","BK4588","RAPP","BK4023","BK4585","BK4007","BK4587","BK4528"],"gpt_icon":0},{"id":"2601366454","title":"Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366454?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:55","pubTimestamp":1767873353,"startTime":"0","endTime":"0","summary":"Paul Matteis, an analyst from Stifel Nicolaus, reiterated the Buy rating on Rapport Therapeutics, Inc.. The associated price target was raised to $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/rapport-therapeutics-accelerated-rap-219-epilepsy-path-to-phase-3-and-strategic-pipeline-refocus-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/rapport-therapeutics-accelerated-rap-219-epilepsy-path-to-phase-3-and-strategic-pipeline-refocus-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP"],"gpt_icon":0},{"id":"2601844753","title":"Have Rapport Therapeutics Insiders Been Selling Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2601844753","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601844753?lang=en_us&edition=fundamental","pubTime":"2026-01-08 02:47","pubTimestamp":1767811661,"startTime":"0","endTime":"0","summary":"Anyone interested in Rapport Therapeutics, Inc. ( NASDAQ:RAPP ) should probably be aware that the Founder & Chief...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/have-rapport-therapeutics-insiders-been-selling-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/have-rapport-therapeutics-insiders-been-selling-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2601708888","title":"Rapport Therapeutics Inc - FDA Allows Rap-219 Advancement Into Registrational Trials for Fos","url":"https://stock-news.laohu8.com/highlight/detail?id=2601708888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601708888?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:00","pubTimestamp":1767787245,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y7184:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2601705578","title":"Rapport Therapeutics Inc: Accelerated Initiation of Rap-219 Phase 3 Program Expected in Q2 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601705578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601705578?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:00","pubTimestamp":1767787245,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y7184:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2601705558","title":"Rapport Therapeutics Inc: Plans to Initiate a Phase 3 Trial of Rap-219 in Pgtcs in First Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2601705558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601705558?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:00","pubTimestamp":1767787245,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y7184:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2601702078","title":"Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2601702078","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601702078?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:00","pubTimestamp":1767787200,"startTime":"0","endTime":"0","summary":"U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214393/0/en/Rapport-Therapeutics-Announces-Accelerated-Initiation-of-RAP-219-Phase-3-Program-Expansion-of-Epilepsy-Portfolio-and-Continued-Progress-Across-the-Pipeline.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","RAPP"],"gpt_icon":0},{"id":"2593312466","title":"Rapport Therapeutics (RAPP): Valuation Check After Joining the S&P Pharmaceuticals Select Industry Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2593312466","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593312466?lang=en_us&edition=fundamental","pubTime":"2025-12-23 09:18","pubTimestamp":1766452711,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) just joined the S&P Pharmaceuticals Select Industry Index, a move that can quietly reshape its shareholder base as index funds and sector ETFs adjust their holdings.\nSee our latest analysis for Rapport Therapeutics.\nThe index inclusion caps a strong run for Rapport, with a 19.7% 3 month share price return and 73.5% year to date share price return at the latest $31.9 close, alongside a 76.9% 1 year total shareholder return that signals building momentum.\nIf this...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/rapport-therapeutics-rapp-valuation-check-after-joining-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/rapport-therapeutics-rapp-valuation-check-after-joining-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLCT","RAPP","BK4007"],"gpt_icon":0},{"id":"2592630501","title":"How RAP-219 Phase 2a Data and 2026 Phase 3 Plans At Rapport Therapeutics (RAPP) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2592630501","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592630501?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:23","pubTimestamp":1766136188,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics recently reported new data and post hoc analyses from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures, presented at the 2025 American Epilepsy Society Meeting, highlighting statistically significant improvements in several seizure-related patient-reported outcomes and confirming target engagement in key brain regions.\nThe company also outlined plans for an end-of-Phase 2 meeting with the FDA and the potential launch of two pivotal Phase 3 trials in...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/how-rap-219-phase-2a-data-and-2026-phase-3-plans-at-rapport","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/how-rap-219-phase-2a-data-and-2026-phase-3-plans-at-rapport","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RAPP","BK4007","AI"],"gpt_icon":0},{"id":"2592435181","title":"Rapport Therapeutics CEO Abraham Ceesay Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592435181","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592435181?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:11","pubTimestamp":1766092299,"startTime":"0","endTime":"0","summary":"Abraham Ceesay, Chief Executive Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL75lMTD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Rapport Therapeutics CEO Abraham Ceesay Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2592958536","title":"Rapport Therapeutics Chief Scientific Officer David Bredt Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592958536","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592958536?lang=en_us&edition=fundamental","pubTime":"2025-12-17 06:07","pubTimestamp":1765922862,"startTime":"0","endTime":"0","summary":"David Bredt, Chief Scientific Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL7pT9VR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rapport Therapeutics Chief Scientific Officer David Bredt Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2591849695","title":"Assessing Rapport Therapeutics (RAPP) Valuation After Positive RAP-219 Phase 2a Epilepsy Data and Phase 3 Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2591849695","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591849695?lang=en_us&edition=fundamental","pubTime":"2025-12-15 08:20","pubTimestamp":1765758031,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) just put RAP-219 squarely on investors radar, unveiling detailed Phase 2a epilepsy data at the American Epilepsy Society meeting that backs up earlier efficacy signals and clarifies the path toward pivotal Phase 3 trials.\nSee our latest analysis for Rapport Therapeutics.\nThe latest RAP-219 update lands on top of already strong momentum, with a roughly 24 percent 1 month share price return and a year to date share price return of about 65 percent. This suggests...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/assessing-rapport-therapeutics-rapp-valuation-after-positive","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/assessing-rapport-therapeutics-rapp-valuation-after-positive","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RAPP"],"gpt_icon":0},{"id":"2590326824","title":"Rapport Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2590326824","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590326824?lang=en_us&edition=fundamental","pubTime":"2025-12-10 02:33","pubTimestamp":1765305180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 13:33 ET (18:33 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":101,"code":"91000000","status":"200"}]}}